In line with its strategy to establish its presence in the US branded market, Aurobindo has through its subsidiary Acrotech Biopharma acquired seven marketed oncology injectables from Spectrum Pharmaceuticals in a deal worth up to US$300 million.
Aurobindo is set to expand its presence in the US branded market after snapping up through its Acrotech Biopharma subsidiary seven marketed oncology injectable products from Spectrum Pharmaceuticals.
For an upfront purchase price of US$160 million in cash, plus up to US$140 million in regulatory and sales-based milestones,...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
